BerGenBio ASA 2023 AR2
The report highlights BerGenBio's progress in 2023, focusing its clinical strategy on selective AXL inhibition with bemcentinib for first-line STK11-mutated non-small cell lung cancer (NSCLC) and severe respiratory infections. The company expanded its Phase 1b/2a clinical trial to 33 sites across seven countries and successfully executed a Rights Issue that secured NOK 250 million in funding. Additionally, BerGenBio implemented a focused strategy that resulted in a 37% reduction in cash use and a significant reduction in operating loss to NOK 191.8 million. On the ESG front, the company mapped its greenhouse gas emissions, reporting total emissions of 76.91 t CO2e, and successfully integrated a supplier ESG self-assessment questionnaire.
Company: BerGenBio ASA
Sector: Health Care
Country: Norway
Year: 2023
Type: AR2
Pages: 93
BerGenBio ASA
Annual Report And Accounts
The report highlights BerGenBio's progress in 2023, focusing its clinical strategy on selective AXL inhibition with bemcentinib for first-line STK11-mutated non-small cell lung cancer (NSCLC) and severe respiratory infections. The company expanded its Phase 1b/2a clinical trial to 33 sites across seven countries and successfully executed a Rights Issue that secured NOK 250 million in funding. Additionally, BerGenBio implemented a focused strategy that resulted in a 37% reduction in cash use and a significant reduction in operating loss to NOK 191.8 million. On the ESG front, the company mapped its greenhouse gas emissions, reporting total emissions of 76.91 t CO2e, and successfully integrated a supplier ESG self-assessment questionnaire.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women on Board
Women in Management
Workplace Fatalities
Employees